Finasteride Tablet, Film Coated
Product Images NDC 55154-8083

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Finasteride (NDC 55154-8083). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Cardinal Health 107, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

6bb2a221 010a 4967 A1eb C925b9303548 00

Label for Finasteride tablets, USP 5 mg, film-coated oral tablets. Package contains 10 tablets. Includes dosage and storage instructions, warnings, and manufacturer and distributor information. The label states the product is prescription-only and notes it is not child-resistant. Manufactured by Camber Pharmaceuticals and Ascent Pharmaceuticals, distributed by Major Pharmaceuticals and Cardinal Health.*

FDA Label Image

Address.jpg (Address)

FDA Label Image

Address3.jpg (Address3)

FDA Label Image

Figure1.jpg (Figure1)

A line graph comparing the mean change from baseline over a four-year period for Finasteride 5 mg film-coated tablets and placebo groups. The graph shows data points from baseline through Year 4, with two distinct lines representing Finasteride and placebo, indicating a greater reduction over time for Finasteride than placebo.*

FDA Label Image

Figure2.jpg (Figure2)

A line chart titled 'Figure 2 Percent of Patients Having Surgery for BPH, Including TURP,' comparing the percent of patients over time in months between Finasteride and placebo groups. The y-axis shows percent of patients (0% to 15%) and the x-axis shows observation time in months (0 to 48). The Finasteride group shows a lower percent of patients undergoing surgery compared to placebo over time. A legend identifies the lines for Finasteride and placebo. Tabular data below the graph presents number of events, cumulative events, and patients at risk per year for both groups.*

FDA Label Image

Figure3.jpg (Figure3)

A line graph showing mean percent change from baseline over four years for patients on Finasteride 5 mg and placebo. The X-axis represents time points from baseline to year 4, and the Y-axis represents mean percent change. Two lines depict data trends for placebo and Finasteride groups, with sample sizes noted for each time point.*

FDA Label Image

Figure4.jpg (Figure4)

A line graph depicting the percentage of events over time in years from randomization, comparing four groups: Placebo, Finasteride, Doxazosin, and Combination. The y-axis represents the percent with event (0 to 25%), and the x-axis shows years from 0 to 5.5. The Placebo group shows the highest event rate over time, while the Combination group shows the lowest.*

FDA Label Image

Structure.jpg (Structure)

Chemical structure diagram of Finasteride illustrating the molecular framework with labeled atoms and bonds of the active ingredient Finasteride.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.